Valion Bio names new COO, sees 11.7% stock surge after funding and reverse-split vote

What happened

Valion Bio, Inc. (Nasdaq: VBIO), a pharmaceutical company based in San Antonio, Texas, disclosed several corporate actions in an 8-K filed August 17, 2026. The company appointed Lisa Wolf as Chief Operating Officer, effective August 16, 2026, while she continues as Chief Financial Officer. On the same date, Michael K. Handley was terminated from his position as Chief Executive Officer. The filing does not state a reason for his termination.

The company also entered into a letter agreement with 3i, LP to issue 1,500 shares of Series B Non-Voting Convertible Preferred Stock at $1,000 per share, along with warrants to purchase common stock, for an aggregate purchase price of $1.5 million. The securities were sold under an exemption from registration, and the company noted it is negotiating additional funding tranches but has no definitive agreements yet.

Additionally, at a special stockholder meeting on August 14, 2026, shareholders approved a proposal granting the board discretion to effect a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-50, to be determined within twelve months. They also approved a proposal to adjourn the meeting if needed, though the chair did not exercise that option.

The stock rose 11.7% on the day of the filing, closing at $0.191 per share on volume of approximately 171 million shares, more than 52 times the average volume.

The funding and royalty agreement

The letter agreement with 3i, LP is part of a Series B Preferred Purchase Agreement originally dated April 29, 2025, as amended. Under the new agreement, Valion Bio will issue preferred stock and warrants, with the number of underlying common shares and warrant exercise price calculated per the original agreement.

Additionally, the company, 3i, and other purchasers from a separate December 2025 agreement will enter into a royalty agreement. Under that agreement, 3i and the other purchasers will receive cash payments equal to 5% of the gross revenue of Velocity Bioworks, Inc., a wholly-owned subsidiary of Valion Bio, for ten years.

The company's annual revenue for the period ending December 31, 2024, was $780,000, according to data provided. The company did not disclose further details about its revenue or the reason for the funding.

Shareholder vote details

At the special meeting, shares of Series A, B, and C preferred stock were not entitled to vote, so only common stockholders voted. Approximately 1,940,835 of the 4,151,259 outstanding common shares (46.75%) were represented, establishing a quorum.

Proposal No. 1, the reverse stock split authorization, passed with 1,243,030 votes for, 697,127 against, and 678 abstentions. Proposal No. 2, regarding adjournment, also passed with 1,242,480 for, 686,908 against, and 11,447 abstentions, but was not used.

The reverse stock split, if implemented, would reduce the number of outstanding shares and typically aims to raise the per-share price, which may help a company maintain listing requirements on Nasdaq. The board has up to twelve months to choose a ratio.

What this means

This 8-K combines several disclosures: unregistered sales of equity (Item 3.02), officer changes (Item 5.02), shareholder vote results (Item 5.07), and other events (Item 8.01). An 8-K is a current report that companies must file with the SEC within four business days of certain material events. Here, the company filed on the same day as the funding agreement.

The issuance of preferred stock and warrants to 3i is an unregistered sale, meaning it was exempt from SEC registration under Section 4(a)(2) of the Securities Act, which allows private placements to accredited investors without a public offering. The warrants give 3i the right to buy common stock at a future price set by the purchase agreement.

The royalty agreement is a way for investors to receive a percentage of future revenue from a subsidiary, which can provide them with ongoing payments without taking an equity stake. This is a form of financing that companies with limited revenue might use.

The appointment of Lisa Wolf as COO while she remains CFO is a management change that the company is required to disclose. The termination of Michael Handley as CEO is also disclosed, but the filing does not explain why he was terminated, and this article does not speculate.

The reverse stock split approval gives the board flexibility to adjust the share price, which is a common step for companies facing potential delisting due to low share prices. The Nasdaq has minimum bid price requirements. However, the company's filing does not state whether it is currently at risk of delisting.

Investors should note that the stock's large volume and price increase could be driven by the funding and management changes, but the source materials do not explicitly connect the two. The future direction of the stock is not predictable from this filing.